BEIJING, June 06, 2025 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) (“QuantaSing” or the “Company”), a leading lifestyle solution provider, today announced its unaudited financial results for the third quarter of the fiscal year ending June 30, 2025 (the “third quarter of FY 2025”, which refers to the quarter from January 1, 2025 to March 31, 2025). Business and Financial Highlights for the Third Quarter of FY 2025 Revenues for the third quarter of FY 2025 were RMB570.7 million (US$78.6 millio ...

SHENZHEN, China, June 06, 2025 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data-driven and AI-powered solutions in Asia, today announced its unaudited financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial and Operational Highlights Robust growth in insurance premiums: Gross written premiums (“GWP”) reached ...

Vesting and settlement of 2022 Conditional Share Awards and Notification of transactions by persons discharging managerial responsibilities Serabi announces that on 5 June 2025 the Board of Directors approved the vesting of Conditional Share Awards that had been granted for the 2022 calendar year pursuant to the Company’s Long Term Incentive Plan (“LTIP”). In aggregate a total of 482,528 new ordinary shares (“the 2022 Awards”) were calculated as being due to vest to participants under the LTIP. The Board h ...

Company announcement no. 21In continuation of Nykredit takeover of Spar Nord Bank (company announcement no. 15/2025) the Bank’s financial calendar for 2025 is updated. Spar Nord Bank now expects to announce the financial statements on the following dates: Date Event 14th August 2025 Semi-Annual Report 30th October 2025 Quarterly Report – Q3 Rune Brandt BørglumCFO Attachment Nr. 21 - Updated financial Calendar for 2025 - UK ...

Core Insights - Vivoryon Therapeutics N.V. presented meta-analysis data for its lead drug varoglutamstat at the 62nd ERA Congress, highlighting significant improvements in kidney function [1][2][3] Group 1: Drug Development and Efficacy - Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with notable anti-inflammatory and anti-fibrotic effects [3] - The Phase 2 studies, VIVIAD and VIVA-MIND, demonstrated statistically significant and clinically meaningful improvements in estimated glomerular filtration rate (eGFR) in elderly patients, with effects sustained from week 24 to week 96 [3] - The meta-analysis indicated a larger effect size in participants with diabetes compared to those without [3] Group 2: Future Plans - The next step involves a dedicated Phase 2b trial focusing on patients with diabetic kidney disease, aiming to assess efficacy on eGFR and gather data on proteinuria and other kidney-specific markers [4] Group 3: Presentation Details - The presentation took place on June 6, 2025, at 8:15 am CEST in Vienna, Austria, led by Frank Weber, CEO of Vivoryon Therapeutics [5]

Core Insights - Burning Rock Biotech Limited reported a revenue of RMB 133.1 million (US$ 18.3 million) for Q1 2025, marking a 5.9% increase from RMB 125.6 million in Q1 2024 [3] - The company achieved a gross profit of RMB 97.4 million (US$ 13.4 million) for the same period, representing a 13.7% increase from RMB 85.7 million in Q1 2024, with a gross margin of 73.2% [5][8] - The net loss for Q1 2025 was RMB 13.5 million (US$ 1.9 million), a significant reduction from a net loss of RMB 121.5 million in Q1 2024 [10] Financial Performance - Revenue from the central laboratory business decreased by 19.6% to RMB 38.3 million (US$ 5.3 million) in Q1 2025, primarily due to a reduction in the number of tests [6] - Revenue from the in-hospital business increased by 0.5% to RMB 57.7 million (US$ 7.9 million), driven by growth in sales volume [6] - Revenue from pharma research and development services surged by 79.9% to RMB 37.1 million (US$ 5.1 million), attributed to increased development and testing services [6] Cost Management - Cost of revenues decreased by 10.6% to RMB 35.7 million (US$ 4.9 million) in Q1 2025, aligning with the revenue decline in the central laboratory business [4] - Operating expenses were significantly reduced by 46.8% to RMB 112.6 million (US$ 15.5 million) due to budget control measures and headcount reduction [9] - Research and development expenses decreased by 38.8% to RMB 40.4 million (US$ 5.6 million) [14] Gross Margin Analysis - Non-GAAP gross profit for Q1 2025 was RMB 100.7 million (US$ 13.9 million), an 8.3% increase from RMB 93.0 million in Q1 2024, with a non-GAAP gross margin of 75.6% [8][16] - The gross margin for the central laboratory business improved to 84.1% in Q1 2025 from 77.7% in Q1 2024, driven by cost optimization [5] Cash Position - As of March 31, 2025, the company had cash, cash equivalents, and restricted cash totaling RMB 497.4 million (US$ 68.5 million) [10]

Core Insights - OBI Pharma and TegMine Therapeutics have entered into a Master Services Agreement (MSA) to collaborate on antibody-drug conjugates (ADCs) [1][2] - The partnership aims to leverage OBI's GlycOBI ADC enabling technologies to identify ADC therapeutic candidates for clinical development [2][3] Company Overview - OBI Pharma is a clinical-stage global oncology company based in Taiwan, established in 2002, focusing on developing novel cancer therapies for patients with high unmet medical needs [5] - TegMine Therapeutics, founded in 2017 and based in San Francisco, specializes in developing next-generation antibody-based therapies targeting cancer-associated glycans and glycoproteins [8][9] Technology and Innovation - OBI's GlycOBI technology is a unique glycan-based ADC platform that is compatible with various antibodies, linkers, and payloads, allowing for site-specific homogenous ADCs [4] - The GlycOBI platform utilizes proprietary enzymatic and linker technologies to enhance conjugation efficiency and reduce aggregation propensity, leading to improved antitumor activity and stability [4][6] Strategic Collaboration - The collaboration is expected to combine the strengths of both companies, with OBI's ADC technology complementing TegMine's focus on targeting cancer-specific glycans [3] - Both companies anticipate developing ADCs with unprecedented tumor specificity and therapeutic impact, addressing significant medical needs [3]

Group 1 - UAB "Kvartalas" aimed to raise 5 million euros during the offering of the third tranche of bonds to finance the development of the "Sąvaržėlė" business centre in Vilnius, with the offering period shortened due to high demand, reaching 11.5 million euros in demand within three days [1][2] - The total nominal value of bonds issued in the third tranche was increased from 5 million euros to 10,131,700 euros, with a total of 30,131,700 euros in bonds issued across all tranches [2] - The bonds were publicly offered to retail and institutional investors in the Baltic States, with 181 investors participating, including 153 from Lithuania, 16 from Estonia, and 12 from Latvia [3] Group 2 - The nominal value of one bond is 100 euros, with a fixed annual interest of 8% paid every six months, and redemption scheduled for 19 December 2026, offered at a price corresponding to a 6.75% yield [4]

Core Insights - The Kenyan government plans to implement the Danish F2 digital platform across all government departments to transition to a paperless working environment [1][2] - The initiative aims to enhance transparency and accountability in the public service, ensuring efficient service delivery through clear and auditable processes [3] - The F2 platform, developed in collaboration with the Danish government, is already in use by various Danish ministries and over 75 government organizations [4] Company and Industry Summary - cBrain is contributing its technology to the Kenyan government's strategic collaboration for the F2 platform rollout [2] - The F2 platform is a commercial off-the-shelf (COTS) solution designed specifically for government use, facilitating fast, scalable, and legally compliant digital operations [5] - The platform has been deployed by government authorities across five continents, supporting public sector workflows and compliance needs [5]

Core Insights - Kitron has signed a significant manufacturing agreement valued at approximately EUR 7 million annually with a leading customer in the industrial automation sector, focusing on high-performance drive modules for automation and motion control systems [1][3] - The agreement includes complete box-build services from Kitron's European facilities, with production scheduled to begin in the fourth quarter of 2025 [2] - The contract reflects Kitron's strong position in the Industry market sector, driven by demand for robust and scalable manufacturing solutions in automation and digital control technologies [3] Company Overview - Kitron is a leading Scandinavian electronics manufacturing services company operating in various sectors, including Connectivity, Electrification, Industry, Medical devices, and Defence/Aerospace [4] - The company has operations in multiple countries, including Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, Malaysia, China, and the United States, employing approximately 2,400 people [4] - Kitron reported revenues of EUR 647 million in 2024, indicating a strong financial position [4]